Literature DB >> 21654879

The roles of EZH2 in cell lineage commitment.

Ruey-Hwang Chou, Yung-Luen Yu, Mien-Chie Hung.   

Abstract

Enhancer of zeste homolog 2 (EZH2), a catalytic component of polycomb repressive complex 2 (PRC2), epigenetically regulates chromatin structure and gene expressions through tri-methylation at histone H3K27 and recruitment of DNA methyltransferases for gene silencing. Despite extensive studies of the role of EZH2 in cancer progression and malignancy, increasing evidence also suggest that EZH2 plays a critical role in stem cells renewal, maintenance, and differentiation into specific cell lineages. Here, we review the updated information regarding how EZH2 contributes to stem cell maintenance, cell lineage determination, including myogenesis, adipogenesis, osteogenesis, neurogenesis, hematopoiesis, lymphopoiesis, epidermal differentiation and hepatogenesis, and how EZH2 is regulated by phosphorylation and microRNAs in these processes.

Entities:  

Keywords:  EZH2; cell lineage; differentiation; stem cells

Year:  2011        PMID: 21654879      PMCID: PMC3102568     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  57 in total

1.  MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.

Authors:  Ji-Guang Zhang; Jian-Feng Guo; Dong-Lei Liu; Quan Liu; Jian-Jun Wang
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

2.  Ezh2 expression in astrocytes induces their dedifferentiation toward neural stem cells.

Authors:  Falak Sher; Erik Boddeke; Sjef Copray
Journal:  Cell Reprogram       Date:  2010-10-27       Impact factor: 1.987

3.  The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.

Authors:  Giuseppina Caretti; Monica Di Padova; Bruce Micales; Gary E Lyons; Vittorio Sartorelli
Journal:  Genes Dev       Date:  2004-11-01       Impact factor: 11.361

Review 4.  Polycomb silencers control cell fate, development and cancer.

Authors:  Anke Sparmann; Maarten van Lohuizen
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

5.  Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA.

Authors:  Syuzo Kaneko; Gang Li; Jinsook Son; Chong-Feng Xu; Raphael Margueron; Thomas A Neubert; Danny Reinberg
Journal:  Genes Dev       Date:  2010-12-01       Impact factor: 11.361

6.  Modulation of osteogenesis and adipogenesis by human serum in human bone marrow cultures.

Authors:  R O Oreffo; A S Virdi; J T Triffitt
Journal:  Eur J Cell Biol       Date:  1997-11       Impact factor: 4.492

7.  Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex.

Authors:  João D Pereira; Stephen N Sansom; James Smith; Marc-Werner Dobenecker; Alexander Tarakhovsky; Frederick J Livesey
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-23       Impact factor: 11.205

8.  Differentiation of neural stem cells into oligodendrocytes: involvement of the polycomb group protein Ezh2.

Authors:  Falak Sher; Reinhard Rössler; Nieske Brouwer; Veerakumar Balasubramaniyan; Erik Boddeke; Sjef Copray
Journal:  Stem Cells       Date:  2008-08-07       Impact factor: 6.277

9.  MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors.

Authors:  Su-Li Cheng; Jian-Su Shao; Nichole Charlton-Kachigian; Arleen P Loewy; Dwight A Towler
Journal:  J Biol Chem       Date:  2003-08-18       Impact factor: 5.157

10.  cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin.

Authors:  Der-Chih Yang; Huey-Jen Tsay; Shan-Yang Lin; Shih-Hwa Chiou; Mei-Jane Li; Tai-Jay Chang; Shih-Chieh Hung
Journal:  PLoS One       Date:  2008-02-06       Impact factor: 3.240

View more
  48 in total

Review 1.  The role of epigenetic regulation in stem cell and cancer biology.

Authors:  Lilian E van Vlerken; Elaine M Hurt; Robert E Hollingsworth
Journal:  J Mol Med (Berl)       Date:  2012-06-02       Impact factor: 4.599

Review 2.  Diverse involvement of EZH2 in cancer epigenetics.

Authors:  Pamela Völkel; Barbara Dupret; Xuefen Le Bourhis; Pierre-Olivier Angrand
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

Review 3.  Genetic syndromes caused by mutations in epigenetic genes.

Authors:  María Berdasco; Manel Esteller
Journal:  Hum Genet       Date:  2013-01-31       Impact factor: 4.132

4.  Identification of Novel EZH2 Targets Regulating Osteogenic Differentiation in Mesenchymal Stem Cells.

Authors:  Sarah Hemming; Dimitrios Cakouros; Kate Vandyke; Melissa J Davis; Andrew C W Zannettino; Stan Gronthos
Journal:  Stem Cells Dev       Date:  2016-06-07       Impact factor: 3.272

5.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

Authors:  Michael T McCabe; Heidi M Ott; Gopinath Ganji; Susan Korenchuk; Christine Thompson; Glenn S Van Aller; Yan Liu; Alan P Graves; Anthony Della Pietra; Elsie Diaz; Louis V LaFrance; Mark Mellinger; Celine Duquenne; Xinrong Tian; Ryan G Kruger; Charles F McHugh; Martin Brandt; William H Miller; Dashyant Dhanak; Sharad K Verma; Peter J Tummino; Caretha L Creasy
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

6.  EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms.

Authors:  N Venkatesan; J F Wong; K P Tan; H H Chung; Y H Yau; E Cukuroglu; A Allahverdi; L Nordenskiöld; J Göke; S Geifman-Shochat; V C L Lin; M S Madhusudhan; I-H Su
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

Review 7.  Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Feras Zaiem; Fazlul H Sarkar
Journal:  Ann Transl Med       Date:  2014-06

8.  Wilms tumor suppressor, WT1, suppresses epigenetic silencing of the β-catenin gene.

Authors:  Murielle M Akpa; Diana M Iglesias; Lee Lee Chu; Marta Cybulsky; Cristina Bravi; Paul R Goodyer
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

Review 9.  Therapeutical Strategies for Spinal Cord Injury and a Promising Autologous Astrocyte-Based Therapy Using Efficient Reprogramming Techniques.

Authors:  Hao Yang; Cui-Cui Liu; Chun-Yu Wang; Qian Zhang; Jiang An; Lingling Zhang; Ding-Jun Hao
Journal:  Mol Neurobiol       Date:  2015-04-12       Impact factor: 5.590

10.  Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer.

Authors:  Deborah L Burkhart; Katherine L Morel; Kristine M Wadosky; David P Labbé; Phillip M Galbo; Zafardjan Dalimov; Bo Xu; Massimo Loda; Leigh Ellis
Journal:  Cancer Prev Res (Phila)       Date:  2020-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.